KONTAN.CO.ID - Novavax Inc's COVID-19 vaccine is effective in generating an immune response against the Omicron variant, according to early data published on Wednesday, suggesting that the U.S. drugmaker's existing COVID-19 vaccine can help combat the new Omicron variant. Novavax's two-dose, protein-based vaccine was authorized for use this week by European Union regulators and the World Health Organization. It has previously been approved by countries including Indonesia and the Philippines but not the United States. Novavax said that receiving an additional booster dose of Novavax's vaccine further increased people's immune response to Omicron. The data was taken from Novavax's ongoing studies of its vaccine's effectiveness in adolescents and as a booster.
Novavax says COVID vaccine triggers immune response to Omicron variant
KONTAN.CO.ID - Novavax Inc's COVID-19 vaccine is effective in generating an immune response against the Omicron variant, according to early data published on Wednesday, suggesting that the U.S. drugmaker's existing COVID-19 vaccine can help combat the new Omicron variant. Novavax's two-dose, protein-based vaccine was authorized for use this week by European Union regulators and the World Health Organization. It has previously been approved by countries including Indonesia and the Philippines but not the United States. Novavax said that receiving an additional booster dose of Novavax's vaccine further increased people's immune response to Omicron. The data was taken from Novavax's ongoing studies of its vaccine's effectiveness in adolescents and as a booster.